1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 29,870 | +3,43 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
| CSPC PHARMA | 0,607 | -5,57 % | CLSA Adds Basket Allocation on CSPC PHARMA/HANSOH PHARMA/Hengrui as CN Policy Environment Now More Supportive for Pharmas | ||
| ACADIA PHARMACEUTICALS | 15,845 | +0,28 % | Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders | ||
| SELLAS LIFE SCIENCES | 1,442 | +4,49 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML | - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 271,80 | +0,33 % | Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach | ||
| CATALYST PHARMACEUTICALS | 21,140 | -1,58 % | Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y | ||
| ENZON PHARMACEUTICALS | 0,068 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| OPUS GENETICS | 0,836 | -1,53 % | FDA grants RMAT status to Opus Genetics' OPGx-LCA5 gene therapy | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets | Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,008 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,720 | 0,00 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 1,410 | +11,90 % | Galectin Therapeutics Inc.: Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress | ||
| BIODEXA PHARMACEUTICALS | 1,250 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP | May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted... ► Artikel lesen | |
| PHOTOCURE | 4,215 | -0,47 % | Photocure ASA: Results for the first quarter of 2025 | OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,325 | -11,67 % | ArcticZymes Q1 2025 slides: Revenue dips amid strategic shift, customer base hits record high |
Das Unternehmen NATTOPHARMA ASA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.